|
Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients |
Lessard M, Ouimet D, Leblanc M, Nadeau-Fredette AC, Bell R, Lafrance JP, Pichette V, Vallee M |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Lessard M, Ouimet D, Leblanc M, Nadeau-Fredette AC, Bell R, Lafrance JP, Pichette V, Vallee M. Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients. BMC Nephrology 2014; 15(1): 27 Indexing Status Subject indexing assigned by NLM MeSH Administration, Oral; Bone Density Conservation Agents /administration & Cohort Studies; Cost-Benefit Analysis; Female; Health Care Costs /statistics & Humans; Hydroxycholecalciferols /administration & Hyperparathyroidism, Secondary /drug therapy /economics /etiology; Injections, Intravenous /economics; Male; Middle Aged; Quebec; Renal Dialysis /adverse effects /economics; Renal Insufficiency, Chronic /complications /drug therapy /economics; Retrospective Studies; Treatment Outcome; dosage /economics; dosage /economics; numerical data AccessionNumber 22014011556 Date bibliographic record published 08/04/2014 |
|
|
|